Merck Reports Strong Q3 Results Amid Mixed Outlook
Merck & Co. reported a 4% increase in worldwide sales to $17.3 billion in Q3 2025, driven by strong growth in KEYTRUDA and WINREVAIR, despite declines in GARDASIL sales. The company achieved significant pipeline milestones, including FDA approvals and positive trial results, and raised its full-year sales and EPS outlooks, reflecting ongoing strategic investments and acquisitions. Overall, Merck demonstrated robust financial performance and pipeline progress, positioning itself for continued growth in 2025.